DTIL
Precision·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About DTIL
Precision Biosciences, Inc.
A clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies
Biological Technology
--
03/28/2019
NASDAQ Stock Exchange
108
12-31
Common stock
302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701
--
Precision BioSciences, Inc., is incorporated in Delaware. The company is an advanced gene editing company that utilizes the novel proprietary ARCUS platform to develop in vivo gene editing therapies for complex gene editing, including gene elimination, insertion and excision.
Company Financials
EPS
DTIL has released its 2025 Q3 earnings. EPS was reported at -1.84, versus the expected -2.21, beating expectations. The chart below visualizes how DTIL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
DTIL has released its 2025 Q3 earnings report, with revenue of 13.00K, reflecting a YoY change of -97.74%, and net profit of -21.77M, showing a YoY change of -32.55%. The Sankey diagram below clearly presents DTIL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
